research Il-10 family members as novel responders to genotoxic stress
IL-19 and IL-24 help cells respond to DNA damage and could be targeted for cancer and age-related disease treatments.
Search
for
Sort by
Research
720-750 / 1000+ results
research 220 Dynamic and spatial transcriptional responses in COVID-19-related chilblains
COVID-toes show a unique immune response over time, different from vaccine-related chilblains.
research Modulating immune responses in alopecia: therapeutic insights and potential targets of antisense oligonucleotides
Targeting SIRT1 with antisense oligonucleotides could be a promising treatment for hair loss.
research Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy
Vaccination is crucial for psoriasis patients on immunosuppressive therapy to manage COVID-19 risks.
research British Cosmetic Dermatology Group
Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.
research Epidermal γδ T cells, CD8 T cells and macrophages are increased in number in alopecia areata and express BST2 as part of an interferon-driven antiviral gene signature
In alopecia areata, certain immune cells increase and express a protein linked to immune activation.
research Current options and treatment strategies for alopecia ateata in comorbidity with atopic diseases
Dupilumab and oral JAK inhibitors are effective for treating alopecia areata with atopic diseases.
research Changes in Populations of HLA- DR+CD3+ Cells and CD57–CD16+ Cells in Alopecia areata after Corticosteroid Therapy
Corticosteroid therapy reduces specific immune cells and promotes hair growth in alopecia areata patients.
research 1349 Stimulation of hair follicle stem cell proliferation through an IL-1α dependent activation of γδT-cells
Certain immune cells, when activated by specific signals, can encourage hair growth.
research 1348 Involvement of mast cells and CB1 in the pathogenesis of IgA vasculitis
Mast cells and the CB1 receptor may be key in causing IgA vasculitis.
research Dupilumab and alopecia: A Janus effect
Dupilumab can both heal and cause hair loss.
research 1391 Immune cells may have a role in hair loss process caused by TRPV3 gain-of-function mutation
Immune cells might contribute to hair loss caused by a specific mutation.
research 809 IL-13 protein concentrates in the epidermis of lesional and non-lesional skin of AD patients
IL-13 protein is much higher in the skin of atopic dermatitis patients than in healthy skin.
research Insulin Resistance, Metabolic Syndrome, and Inflammatory Skin Disease
Improving diet and lifestyle can help manage skin conditions linked to insulin resistance and inflammation.
research Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase) inhibitors, cyclosporin A, FK506, ascomycin and rapamycin, on hair growth initiation in mouse: immunosuppression is not required for new hair growth
Cyclosporin A and FK506 can start new hair growth without needing immunosuppression.
research Successful Treatment of Multiple Alopecia Areata With Contact Immunotherapy: Supportive Usage of Oral Antihistamine and Topical Corticosteroid
Alopecia areata was successfully treated with contact immunotherapy, oral antihistamines, and topical corticosteroids.
research LB943 Tofacitinib treatment of inflammatory skin conditions in patients with Down Syndrome
Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
research 64750 Which lessons on the role of TNF-a in hair follicle (patho-)biology can be learned from TNF-a inhibitor-induced alopecia areata?
research Th1 effector CD4 T cells rely on IFN-γ production to induce alopecia areata
CD4 T cells need IFN-γ to cause hair loss in alopecia areata.
research [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
research Enhancement of Immune Responses Elicited by Nanovaccines through a Cross-Presentation Pathway
research Targeting lymphoid-derived IL-17 signaling to delay skin aging
Blocking IL-17 signaling may reduce skin inflammation and delay aging.
research 1379 Cyclosporin A suppresses TGF-β2 expression via calcineurin/NFAT pathway in human dermal papilla cells
Cyclosporin A, a drug, reduces TGF-β2 expression in skin cells, potentially causing excessive hair growth through a process involving the calcineurin/NFAT pathway.
research Altered expression of intracellular Toll-like receptors in peripheral blood mononuclear cells from patients with alopecia areata
Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.
research Dermatological findings in common rheumatologic diseases in children
Children with different rheumatologic diseases have specific skin symptoms that can help with diagnosis.
research Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease
Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
research The effect of inflammatory cytokines on the risk of hypertrophic scar: A Mendelian Randomization Study
Certain proteins can either protect against or increase the risk of hypertrophic scars.
research 396 Vδ1 + T-cells are stress-sentinels in human skin and are implicated in alopecia areata pathogenesis
Vδ1+ T-cells in the skin contribute to hair loss in alopecia areata and could be targeted for treatment.
research Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
research 026 Targeting pathogenic MICA-NKG2D interactions by statins: A novel adjunct treatment strategy for alopecia areata management?
Statins may help treat alopecia areata by reducing harmful immune interactions.